Published in World J Hepatol on June 27, 2013
Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol (2014) 0.93
Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol (2013) 0.92
Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am (2014) 0.82
Clock gene Per2 as a controller of liver carcinogenesis. Oncotarget (2016) 0.76
HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med (2016) 0.75
Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. Infect Dis Poverty (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med (1995) 6.75
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg (2000) 5.79
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med (1991) 5.69
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg (2006) 5.65
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology (2004) 4.26
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology (2003) 4.13
Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg (1993) 3.91
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology (2005) 3.63
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Loco-regional treatment of hepatocellular carcinoma. Hepatology (2010) 3.59
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology (2005) 3.26
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Strategies for safer liver surgery and partial liver transplantation. N Engl J Med (2007) 3.14
Surgery for small liver cancers. Semin Surg Oncol (1993) 3.00
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology (2013) 2.98
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology (1995) 2.63
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg (2007) 2.53
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33
Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol (2010) 2.31
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (2013) 2.30
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg (1997) 2.28
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology (2009) 2.25
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg (2004) 2.20
Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology (2008) 2.11
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology (2005) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer (1992) 2.01
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology (1988) 1.91
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology (2006) 1.90
Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer (2003) 1.86
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol (1990) 1.86
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol (1998) 1.80
Liver transplantation for hepatocellular carcinoma. Semin Liver Dis (1999) 1.78
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol (2011) 1.61
Liver transplantation for fulminant hepatic failure. Semin Liver Dis (1985) 1.56
Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg (2007) 1.56
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology (2001) 1.53
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int (2011) 1.46
Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg (2002) 1.45
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol (2004) 1.40
Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol (2008) 1.40
Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol (2008) 1.33
Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol (2009) 1.31
Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology (2004) 1.31
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut (2002) 1.29
Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl (2005) 1.28
Screening for hepatocellular carcinoma in cirrhosis. J Hepatol (2003) 1.27
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int (2012) 1.22
Live donors in liver transplantation. Gastroenterology (2008) 1.17